Jing Yu
DSC01656.jpg

OPEN INSULIN PLATFORM

A PLATFORM THAT ENABLES PEOPLE TO MAKE SAFE, EFFECTIVE INSULIN AT HOME.

whyareyousnoopinghere.png
Yet almost a century later, the medicine is still beyond the reach of roughly half of the 100 million people around the world who need it.
— Bloomberg Editorial (2018)
 
 

>> DISTRIBUTED PHARMACEUTICALS

The Open Insulin Project is a physical kit, digital platform and supporting service that enables anyone to perform a small-scale biopharmaceutical production of human insulin outside the laboratory.

 
 
 

>> THE (PROBLEM) SPACE OF INSULIN

In 1923, the patent for insulin was sold by scientists for $1. Yet, nearly a century later, the “lack of access to affordable insulin remains a key impediment to successful treatment and results in needless complications and premature deaths” [WHO 2018 REPORT ON DIABETES].

In the USA, 99% of the insulin market is dominated by three pharmaceutical giants that employ evergreening1 to keep their insulin pricing protected under patent while not significantly improving the effect of the medicine they produce2. There are few affordable alternatives.

quote-white.png

HUMAN COST

This lack of accessibility affects people. The cost is felt by people of all social economic levels and the most desperate often take risk-prone measures to handle the pricing. Some ignore their maintenance to cope, others ration their insulin supplies. These measures can have dire short and long term health consequences.

The bottom line is –

Screen Shot 2019-01-16 at 4.51.45 PM.png
 

>> A SYSTEM OUTSIDE THE SYSTEM

 

Open Insulin is an alternative path to insulin for those who cannot afford big pharma insulin. The platform leverages the existing support network among people with diabetes to facilitate forums, insulin subsidizations and troubleshooting between new and experienced brewers.

diagram.png
Screen Shot 2019-01-06 at 9.15.13 PM.png
 

The physical kit pre-packages and automates the most difficult parts of following the insulin protocol. A digital platform is used to educate and enable the user to brew insulin at home. Finally, the service ties each step together and brings an added layer of peer-to-peer support and peer-to-facility verification that fosters a safe, robust network of local insulin producers.

 

>> THE DIGITAL PLATFORM

Both a guide and gatekeeper to the physical components of the kit
screens.png
 

The pH, diO2 and temperature sensors inform the app of the status of the insulin culture. Through the app, the user is taken through step-by-step instruction on how to use the physical kit to make their own insulin at home. Any user action on the physical kit is performed through the digital platform, if any thing goes wrong the digital app will close off access to the physical kit, walk the user through how to request insulin subsidizations and how to safely dispose of their brew.

One example of the digital platform guiding the user through the inoculation step of the process. To view more in-depth walkthroughs and details about the process click here.

 
 
Simple screen by screen wireframes

Simple screen by screen wireframes

 
Long form flow wireframes

Long form flow wireframes

 
Low fidelity UI

Low fidelity UI

 

>> THE SERVICE LAYER

Supporting a community and fostering an ethos of responsibility to take ownership and authorship of ones own medicine and support your neighbors while they do the same.
OIP_cleanservblueprint.png
 

>> THE PHYSICAL COMPONENTS (PROPS)

By far the most expensive part of producing insulin is keeping everything sterile
— Tim Gregory (Pharmaceutical Biochemist)
 
1physproto.png

One of the biggest challenges of the physical kit is ensuring sterility in an at-home environment with users who are not trained in sterile technique3. To circumvent the limitations of at home production, the physical kit is designed to be a closed loop system. The insulin culture will never need to be exposed directly to the environment. To design the components, I conducted a laboratory visit and a technical interview with a pharmaceutical industry expert to understand the specific requirements of a small scale manufacturing kit. At scale mocks were made for the exhibition to demonstrate the size and feel of the full kit at home.

 
 
DSC01656.JPG
 
 
 

>> PROCESS

  1. Desk Research

  2. Interviews

  3. Onsite Visit & Laboratory Visit

  4. Service Blueprint

  5. App Architecture*

  6. Wireframes*

  7. Static UI*

  8. Interactive UI*

  9. UI User Testing

  10. UI Iteration

  11. Technical Interviews

  12. Physical Component Design

  13. Service Iteration

  14. Speculative Physical Component Production

  15. Exhibition*

 
 
 
 

>> OUTCOMES & FUTURE STEPS

The Open Insulin Project artifacts (physical, digital and service) were presented at the 2018 CIID Final Exhibition

components.gif

* The Open Insulin Project is currently ongoing. These artifacts constitutes my design thesis at CIID as well as my contribution to the interdisciplinary work of the Open Insulin Project Team in Oakland, CA as of December 2018. You can find continual updates on the state of the project here or at Open Insulin Project Website

 
 

References

1. “Incremental innovation has repeatedly precluded the formation of a generic insulin industry in North American when earlier patents expired… Pharmaceutical-industry analysts have described a repatenting tactic called evergreening, in which a series of related patents – often on metabolites or optical isomers – extend the life of the product after the initial patent expiration.” – Jeremy A. Greene, M.D., Ph.D. (Why Is There No Generic Insulin? Historical Origins of a Modern Problem, 2015)

2. “While the major cost drivers are hospital and outpatient care, a contributing factor is the rise in cost for analogue insulins which are increasingly prescribed despite little evidence that they provide significant advantages over cheaper insulins” – World Health Organization (Global Report on Diabetes, 2016)

3. Sterile technique is a set of specific practices and procedures performed to make equipment and areas free from all microorganisms and to maintain that sterility” – BC Centre for Disease Control (Clinical Procedures for Safer Patient Care, 2010).